Dipal Doshi, CEO at Entrada Therapeutics, Inc. (TRDA), sold 1,000 shares at $16.17 ($16K) on 2024-06-13, disclosed to the SEC on 2024-06-14.
Scheduled sale ($16k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |
| TRDA | SELL | 2023-12-22 | $15K | — | Filing → |